All lobbying filings

WHITMER & WORRALL, LLC

Lobbying for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Coalition to promote lowering prescription drug prices.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 24

HR 3789
DTC Act of 2025
S 229
DTC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 1041
Affordable Prescriptions for Patients Act
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 3160
PREVAIL Act
S 1533
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
S 1546
Patent Eligibility Restoration Act of 2025
HR 3152
Patent Eligibility Restoration Act of 2025
S 43
Skinny Labels, Big Savings Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
S 1785
No Handouts for Drug Advertisements Act
HR 3010
No Handouts for Drug Advertisements Act
S 1040
Drug Competition Enhancement Act
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 1095
Stop STALLING Act
S 1032
Major Richard Star Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 2630
Saving NSF’s Workforce Act

Lobbying activity 3

Pharmacy

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act.

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025. Issues related to H.R. 1, One Big Beautiful Bill Act.

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. S.43 Skinny Labels, Big Savings Act. H.R. 5526/S. 1954, the Biosimilar Red Tape Elimination Act. S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.